| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dea036d1b8d39c3e2259ef477ab4657c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f5aaa9266073261eeb6d2839429a4d1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3679 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3486
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-362
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D15-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-34 |
| filingDate |
2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f22f53e49f5b68063db11161b7f42fc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23dce8aa2b78df4c854842cbb4948da6 |
| publicationDate |
2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10076600-B2 |
| titleOfInvention |
Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders |
| abstract |
This invention uses “Targeted Apheresis” to treat patients with Rheumatoid Arthritis and other autoimmune and inflammatory disorders. “Targeted Apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents. Removal of these pathogenic and pro-inflammatory elements will ameliorate the symptoms of autoimmune disease and may prolong the period of disease remission. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022008636-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021086259-A1 |
| priorityDate |
2011-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |